Oncogene expression in endocrine pancreatic tumors

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Pancreatic endocrine tumors (PETs) are neoplasms arising from islet cells.
• Understanding the molecular mechanisms driving PET development is crucial for diagnosis and treatment.
• Oncogenes play a significant role in tumorigenesis.

Purpose of the Study:

• To investigate the messenger RNA (mRNA) expression levels of key (proto)oncogenes in pancreatic endocrine tumors.
• To determine the association between specific oncogene mRNA expression and tumor characteristics, including metastatic potential and prognosis.

Main Methods:

• Quantitative analysis of mRNA expression for Ha-ras, Ki-ras, fos, c-myc, N-myc, and sis.
• Comparison of oncogene mRNA levels between five pancreatic endocrine tumors and two non-neoplastic pancreatic tissues.
• Correlation analysis of mRNA expression with histological and biological tumor properties and clinical outcomes.

Main Results:

• Ha-ras and Ki-ras mRNA were significantly overexpressed (up to 42-fold) in all pancreatic endocrine tumors compared to normal tissue.
• Metastatic tumors exhibited 2-6 times higher Ha-ras mRNA levels than benign neoplasias.
• c-myc mRNA levels were higher in normal tissue, and fos mRNA levels showed no significant difference between tumor and normal tissues.

Conclusions:

• Ha-ras and Ki-ras mRNA overexpression is associated with the development of pancreatic endocrine tumors.
• Elevated Ha-ras mRNA levels may serve as a potential biomarker for assessing tumor prognosis and predicting metastatic potential.
• Further research with larger cohorts is warranted to validate these findings.